SEQUANA MEDICAL NV (SEQUA.BR) Stock Price, Forecast & Analysis
Europe • Euronext Brussels • EBR:SEQUA • BE0974340722
SEQUA.BR Key Statistics, Chart & Performance
The current stock price of SEQUA.BR is 0.564 EUR. In the past month the price decreased by -0.7%. In the past year, price decreased by -70.32%.
SEQUA.BR Technical Analysis
SEQUA.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SEQUA.BR. SEQUA.BR may be in some trouble as it scores bad on both profitability and health.
SEQUA.BR Financial Highlights
Over the last trailing twelve months SEQUA.BR reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS decreased by -32.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -355.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEQUA.BR Forecast & Estimates
10 analysts have analysed SEQUA.BR and the average price target is 2.79 EUR. This implies a price increase of 394.32% is expected in the next year compared to the current price of 0.564.
For the next year, analysts expect an EPS growth of 81.63% and a revenue growth 782.35% for SEQUA.BR
SEQUA.BR Ownership
SEQUA.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 16.53 | 113.317B | ||
| 1MDT | MEDTRONIC PLC | 16.13 | 108.304B | ||
| SHL | SIEMENS HEALTHINEERS AG | 17.45 | 48.053B | ||
| 1PHIA | KONINKLIJKE PHILIPS NV | 16.27 | 23.842B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 16.29 | 23.669B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.32 | 23.264B | ||
| BIM | BIOMERIEUX | 18.94 | 11.54B | ||
| DIA | DIASORIN SPA | 17.97 | 4.173B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19.68 | 3.916B | ||
| 1AFX | CARL ZEISS MEDITEC AG - BR | 14.5 | 2.513B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About SEQUA.BR
Company Profile
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Company Info
SEQUANA MEDICAL NV
Kortrijksesteenweg 1112, Sint-Denijs-Westrem
Ghent OOST-VLAANDEREN BE
Employees: 48
Phone: 3292928065.0
SEQUANA MEDICAL NV / SEQUA.BR FAQ
What does SEQUA do?
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
What is the current price of SEQUA stock?
The current stock price of SEQUA.BR is 0.564 EUR. The price decreased by -0.7% in the last trading session.
Does SEQUANA MEDICAL NV pay dividends?
SEQUA.BR does not pay a dividend.
How is the ChartMill rating for SEQUANA MEDICAL NV?
SEQUA.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for SEQUA stock?
SEQUANA MEDICAL NV (SEQUA.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).
What is the market capitalization of SEQUA stock?
SEQUANA MEDICAL NV (SEQUA.BR) has a market capitalization of 38.40M EUR. This makes SEQUA.BR a Nano Cap stock.
What is the ownership structure of SEQUANA MEDICAL NV (SEQUA.BR)?
You can find the ownership structure of SEQUANA MEDICAL NV (SEQUA.BR) on the Ownership tab.